Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma

Non-melanoma skin cancer (NMSC) includes a wide range of cutaneous tumors, the most frequent of which are basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC). Although NMSC is usually cured by surgical resection, in rare cases it can progress to locally advanced and metastatic disease. Risk factors for advanced disease include comorbidities, neglect, and immunosuppression. Advanced NMSC may require systemic treatment if surgery and radiation are not feasible. Chemotherapy, epidermal growth factor receptor (EGFR) inhibitors in CSCC, and hedgehog inhibitors in BCC have been used but are generally of limited benefit, with responses often short-lived and toxicity issues. Given the high mutational burden of NMSC, the use of immunotherapy has been investigated and two anti-PD-1 antibodies, cemiplimab and pembrolizumab, are approved for the treatment of advanced CSCC not curable by surgery or radiation. Both have shown durable responses with good tolerability in patients in phase II trials and anti-PD-1 therapy is now the standard of care for locally advanced and metastatic CSCC. PD-1 blockade is also approved as second-line therapy in advanced BCC, with frequent and durable responses after failure on hedgehog inhibitor therapy. PD-1 checkpoint inhibition is being assessed for NMSC in combination with other modalities, including oncolytic viruses and EGFR inhibitors. Adjuvant and neoadjuvant use of cemiplimab and pembrolizumab is also being investigated with several ongoing trials. Further clinical trials of immunotherapy must be prioritized in NMSC for further improvement in outcomes.

[1]  C. Massone,et al.  The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts , 2022, Cancers.

[2]  C. Dessinioti,et al.  Overview of guideline recommendations for the management of high‐risk and advanced cutaneous squamous cell carcinoma , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  R. Dummer,et al.  Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma , 2021, Oncotarget.

[4]  C. Garbe,et al.  Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany , 2021, Acta dermato-venereologica.

[5]  P. Ascierto,et al.  Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. , 2021, European journal of cancer.

[6]  R. Dummer,et al.  1089TiP Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma , 2021, Annals of Oncology.

[7]  J. Haanen,et al.  1062P Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands , 2021, Annals of Oncology.

[8]  G. Daniels,et al.  1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS] , 2021, Annals of Oncology.

[9]  K. Kähler,et al.  1095TiP Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview , 2021, Annals of Oncology.

[10]  A. Hauschild,et al.  1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results , 2021, Annals of Oncology.

[11]  A. Hauschild,et al.  Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis , 2021, Journal for ImmunoTherapy of Cancer.

[12]  S. Billan,et al.  Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Jason M. Johnson,et al.  Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.

[14]  A. Hauschild,et al.  Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[15]  T. Ow,et al.  Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp , 2021, Current oncology.

[16]  K. Harrington,et al.  422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts , 2020 .

[17]  R. Fontana,et al.  A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. , 2020, The oncologist.

[18]  P. Petrow,et al.  Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Davies,et al.  Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy , 2020, Cancer medicine.

[20]  I. Lowy,et al.  A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). , 2020 .

[21]  C. Berking,et al.  Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.

[22]  P. Mohr,et al.  Estimating prevalence and incidence of skin cancer in Germany , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[23]  S. Arron,et al.  Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  R. Birhiray,et al.  Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation. , 2019, Journal of oncology practice.

[25]  C. Schmults,et al.  Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.

[26]  Helen X. Chen,et al.  SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. , 2019, Journal of Clinical Oncology.

[27]  G. Daniels,et al.  KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma. , 2019, Journal of Clinical Oncology.

[28]  J. Taube,et al.  A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or metastatic basal cell carcinoma (mBCC). , 2019, Journal of Clinical Oncology.

[29]  Ansuman T. Satpathy,et al.  Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study , 2018, Journal of the American Academy of Dermatology.

[30]  P. Lefrançois,et al.  Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta‐analysis , 2018, Journal of the American Academy of Dermatology.

[31]  H. C. de Vijlder,et al.  Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study , 2018, The British journal of dermatology.

[32]  A. Sisk,et al.  PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report , 2018, BMC Nephrology.

[33]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[34]  Helen X. Chen,et al.  A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). , 2018 .

[35]  J. Califano,et al.  Comparison of Tumor Classifications for Cutaneous Squamous Cell Carcinoma of the Head and Neck in the 7th vs 8th Edition of the AJCC Cancer Staging Manual , 2017, JAMA dermatology.

[36]  K. May,et al.  Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature , 2016, American journal of clinical oncology.

[37]  T. Chan,et al.  The role of neoantigens in response to immune checkpoint blockade. , 2016, International immunology.

[38]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[39]  A. Chang,et al.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations , 2014, Current Dermatology Reports.

[40]  A. Qureshi,et al.  Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Dummer,et al.  Basal cell carcinoma: a paradigm for targeted therapies , 2013, Expert opinion on pharmacotherapy.

[42]  W. Hwang,et al.  Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. , 2013, JAMA dermatology.

[43]  E. Dennett,et al.  The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors , 2012, Journal of surgical oncology.

[44]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[45]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[46]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[47]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.